Momordica charantia L. improves airway hyperresponsiveness and suppresses inflammation in a murine model of allergic asthma

Allergol Immunopathol (Madr). 2022 Mar 1;50(2):115-123. doi: 10.15586/aei.v50i2.577. eCollection 2022.

Abstract

Objective: To evaluate the effect of a hydroethanolic extract of Momordica charantia L. ("bitter melon", Cucurbitaceae) leaves (MCHA) on ovalbumin (OVA)-induced asthma model. Balb/c mice were sensitized twice and challenged for 4 alternate days with OVA and then treated with MCHA (500 mg/kg) for 7 consecutive days.

Methods: Control groups received treatment with normal saline or dexamethasone (2 mg/kg) on the same day. We assessed in vivo bronchial hyperresponsiveness and ex-vivo inflammation and mucus production in bronchoalveolar lavage (BAL), lung homogenates, and lung tissue.

Results: MCHA significantly improved airway hyperresponsiveness near baseline levels. MCHA administration significantly improved airway and lung inflammation, demonstrated by decreased total and inflammatory cells in BAL, lower levels of IL-5 and IL-13 in lung homogenate, and fewer inflammatory cells in lung tissue. Additionally, MCHA significantly diminished goblet cells in lung tissue.

Conclusions: Administration of a hydroethanolic extract of M. charantia leaves was effective in treating OVA-induced asthma in an animal model.

Keywords: Cucurbitaceae; allergy; herbal medicine; inflammation; ovalbumin.

MeSH terms

  • Animals
  • Asthma* / drug therapy
  • Bronchial Hyperreactivity* / drug therapy
  • Bronchoalveolar Lavage Fluid
  • Cytokines
  • Disease Models, Animal
  • Humans
  • Inflammation / drug therapy
  • Lung
  • Mice
  • Mice, Inbred BALB C
  • Momordica charantia*
  • Ovalbumin

Substances

  • Cytokines
  • Ovalbumin